EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation

Peter Arthur-Farraj, Andrea Loreto

Trends in Pharmacological Sciences · 2025-11 · 46 (11) · 1105-1116

DOI: 10.1016/j.tips.2025.09.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2025-11. Verfasst von Peter Arthur-Farraj und 1 weiteren Autor:innen. Beteiligte Einrichtung: Blizard Institute, Barts and London School of Medicine and Dentistry, Queen Mary University London, London, UK; John Van Geest Centre for Brain Repai…. Hauptthemen laut MEDLINE: Armadillo Domain Proteins, Cytoskeletal Proteins, Neuroprotective Agents, Neurodegenerative Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Sydney, Queen Mary University of London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sterile alpha and TIR motif-containing protein 1 (SARM1),is a central enzyme that drives programmed axon degeneration and has gathered significant interest as a therapeutic target. Despite preclinical development of inhibitory therapeutic approaches, clear evidence of the role of SARM1 in human neurodegeneration had been missing until recently. New discoveries demonstrate SARM1 involvement in widespread human neurodegenerative processes. Advances in understanding the mechanism of action of SARM1 have revealed key properties for developing the next generation of SARM1 inhibitors for neuroprotection. Unexpectedly, recent discoveries of pyridine-derived specific SARM1 activators have expanded the therapeutic possibilities for SARM1 beyond neuroprotection to include neuroablation. In this review, we discuss evidence linking SARM1 to human disease and the current challenges to developing safe and effective inhibitors. We also review the emerging field of SARM1 activators and their potential for the development of highly selective neuroablative therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Armadillo Domain ProteinsCytoskeletal ProteinsNeuroprotective AgentsNeurodegenerative DiseasesHumansAnimalsNeuroprotection

Stichwörter der Autor:innen

NAD(+)SARM1botulinum toxinneuroablativepyridinevacor

Substanzen

Armadillo Domain ProteinsSARM1 protein, humanCytoskeletal ProteinsNeuroprotective Agents

Autor:innen und Institutionen

  • Blizard Institute, Barts and London School of Medicine and Dentistry, Queen Mary University London, London, UK; John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Robi…
  • Neuroscience, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Save Sight Institute, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia;…

Förderung

  • University of Sydney
  • Queen Mary University of London

Zitieren

APA

Arthur-Farraj, P., & Loreto, A. (2025). Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation. Trends in Pharmacological Sciences, 46(11), 1105-1116. https://doi.org/10.1016/j.tips.2025.09.003

Vancouver

Arthur-Farraj P, Loreto A. Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation. Trends in Pharmacological Sciences. 2025;46(11):1105-1116. doi:10.1016/j.tips.2025.09.003

BibTeX
@article{ArthurFarraj2025,
  author = {Arthur-Farraj, Peter and Loreto, Andrea},
  title = {Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation},
  journal = {Trends in Pharmacological Sciences},
  year = {2025},
  volume = {46},
  number = {11},
  pages = {1105--1116},
  doi = {10.1016/j.tips.2025.09.003}
}
Kostenlos starten →